| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f65ba981979b4349e3d3e2d25208b630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_237eb9f6557f67ff65eb8bc3d4dddf17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3b2cf9e2bc59533fbdfce7b8d4c25ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50fe87d57b42b76b25ea5a39da23bb12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47B2200-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47G1-0616 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2006-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c54cecb5d87162b393c749378c3232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab5681b4a6b211081e41f06c1345d254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78229ed7fcd14b466c5d849ed3a3b328
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c202d2a3fdcc9e52d104641b108b7e82 |
| publicationDate |
2007-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007269509-A1 |
| titleOfInvention |
Enteric Coated Pharmaceutical Oral Formulations Comprising Acid-Labile Active Substances, and a Method Thereof |
| abstract |
This invention relates to an oral pharmaceutical formulation formed by a direct coating of an enteric layer containing polyethylene glycol as a plasticizer on a core containing an acid-labile pantoprazole, and its manufacturing method. The enteric-coated oral pharmaceutical formulation of this invention, which combines directly a core containing an acid-labile pantoprazole and an enteric layer in the absence of an inert intermediate layer, is able to improve the storage stability of the acid-labile pantoprazole and maximize the bioavailability and oral absorption rates via preventing related substances from increasing. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012128764-A1 |
| priorityDate |
2005-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |